Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

atient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, and June 27, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor:

Stern Investor Relations, Inc.

212-362-1200

lilian@sternir.com

Media:

Andrea tenBroek

Schwartz Communications

781-684-0770

tapestry@schwartz-pr.com


'/>"/>
SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Therapeutics to 2020 - Broadened Diagnostic ... Drive Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 ...
(Date:8/28/2014)... Ohio , Aug. 28, 2014  A ... competition in generics are adding pressure to pharmaceutical, ... resources. Company resources continue to shrink and approval ... This has led companies to look for additional ... commercialization and for keeping approved products on the ...
(Date:8/28/2014)... 28. August 2014 Sequent ... der Patientenrekrutierung für eine IDE-Pivot-Studie („IDE" ... Beurteilung der Sicherheit und Wirksamkeit des ... („WEB") bekanntgegeben. Adam Arthur, MD, Dozent an ... Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der WEB-IT-Studie, ...
Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 84 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3
... European Association for the Study of ... Diabetes Annual Meeting, ... Annual Meeting of the European Association for the Study,of Diabetes demonstrate ... cardiovascular disease in patients with type 2,diabetes. ACTOS is an oral ...
... Therapy, ALEXANDRIA, La., Sept. 18 Life ... NJ, an emerging provider of,groundbreaking medical devices for ... ThermoSuit(R) System has been granted European CE,Mark (Conformite ... indicated, e.g., to induce hypothermia in patients to,preserve ...
Cached Medicine Technology:ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 2ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 3Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System 2
(Date:8/28/2014)... August 28, 2014 Millennium Treatment ... throughout September. This month will be a celebration ... mental health services. Along with other treatment facilities ... helping to spread the word about this national ... honoring the work of treatment and recovery professionals, ...
(Date:8/28/2014)... Nashville, TN (PRWEB) August 28, 2014 ... the insurance industry on the Internet will now have ... Quotes Pros company. In one click this year, some ... presented at http://quotespros.com/life-insurance.html . , The promoted ... the Quotes Pros finder tool represent popular policies. The ...
(Date:8/28/2014)... ABC television stars will join forces this Labor ... Telethon airing Sunday, Aug. 31, 9/8c on ABC television ... awareness to help save and improve the lives of ... tuning into the 2014 telethon to benefit the Muscular ... some of the network’s leading stars, including Alyssa Milano ...
(Date:8/28/2014)... Pittsburgh, PA (PRWEB) August 28, 2014 ... Ready Nutrition announced today a regional partnership designed ... and goal planning for competitive young athletes, scholastic ... , “Our partnership’s Strong Body & Mind Initiative ... that addresses both the physical and mental dynamics ...
(Date:8/28/2014)... San Mateo, CA (PRWEB) August 28, 2014 ... announce that the MRI Technology program is re-accredited for ... Registry of Magnetic Resonance Imaging Technologists (ARMRIT). , ... re-accreditation. We are constantly improving our program to make ... There is a lot of interest in MRI field ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... major league pitcher , FRIDAY, Oct. 30 (HealthDay News) -- ... than a second, it curves and then drops, baffling the ... correctly, is one of baseball,s most daunting pitches. For more ... sworn that the ball seems to have a life of ...
... Partnership to scale ... ... for AIDS Relief (PEPFAR), the largest commitment ever by any nation to combat a single ... Ambassador Eric Goosby, U.S. Global AIDS Coordinator, who oversees implementation of PEPFAR , in ...
... Oct. 30 NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY ... antifungal activity in an established pre-clinical infected nail model ... at the 47th Annual Meeting of the Infectious Diseases ... tests both the penetration of the nail as well ...
... 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the ... INTUNIV (guanfacine) Extended Release Tablets, at a major psychiatric ... study was to assess the change from baseline on ... Long Form (CPRS-R:L) in patients ages 6 to ...
... ,Charles Drew University has ... the university,s long-term, UCLA partnership aimed at reducing the risk of ... The National Institutes of Health, the National Cancer Institute and the ... Cancer Center Partnership. An additional $4.5 million was allocated to ...
... ... Kentucky felt his heart racing after playing Millsaps College homecoming game on Saturday, October 24, ... Jackson, MS (Vocus) ... his heart racing after playing Millsaps College homecoming game on Saturday, October 24, 2009. , ...
Cached Medicine News:Health News:Scientist Throws Curve Into Breaking-Ball Debate 2Health News:Scientist Throws Curve Into Breaking-Ball Debate 3Health News:U.S. President's Emergency Plan for AIDS Relief Joins mHealth Alliance 2Health News:U.S. President's Emergency Plan for AIDS Relief Joins mHealth Alliance 3Health News:NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis 2Health News:NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis 3Health News:NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis 4Health News:INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale 2Health News:INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale 3Health News:Charles Drew University awarded $9.8 million 2Health News:College Middle Line Backer Treated for Wolff Parkinson White Syndrome at Baptist Cardiovascular Services 2Health News:College Middle Line Backer Treated for Wolff Parkinson White Syndrome at Baptist Cardiovascular Services 3
... System Produces Type I Water Directly from Tap, ... for scientists who need 5 to 15 L ... have easy access to acceptable quality pretreated water. ... L/min of ultrapure (Type I) water on demand, ...
... weighing mechanism for speed, stability and ... analog display modes, multiple units of ... functions, auto print, and GLP/GMP/ISO output ... built-in clock. Touch-key calibration with external ...
... for speed, stability and durability. Back-lighted ... modes, multiple units of measure, piece ... print, and GLP/GMP/ISO output including date ... Built-in, motor-driven internal calibration mass ...
... - Battery Powered (6 size AA required). ... (g, ct, oz, ozt, GN, dwt, mom, ... and Percent Measure functions, Auto Print. Optional ... AC adapter may be ordered for AC ...
Medicine Products: